Orlistat
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
Empros Pharma AB · Phase 1/2 · Completed · Enrollment 156
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| EMP16-02 120 mg orlistat/40 mg acarbose | n/r | n/r | n/r | n/r |
| EMP16-02 150 mg orlistat/50 mg acarbose | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- EMP16-02 120 mg orlistat/40 mg acarbose: endpoint not reported
- EMP16-02 150 mg orlistat/50 mg acarbose: endpoint not reported
- Placebo: endpoint not reported